JP2023507739A5 - - Google Patents

Info

Publication number
JP2023507739A5
JP2023507739A5 JP2022537007A JP2022537007A JP2023507739A5 JP 2023507739 A5 JP2023507739 A5 JP 2023507739A5 JP 2022537007 A JP2022537007 A JP 2022537007A JP 2022537007 A JP2022537007 A JP 2022537007A JP 2023507739 A5 JP2023507739 A5 JP 2023507739A5
Authority
JP
Japan
Prior art keywords
subject
composition according
composition
atrasentan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537007A
Other languages
English (en)
Japanese (ja)
Other versions
JP7624995B2 (ja
JP2023507739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065311 external-priority patent/WO2021126977A1/en
Publication of JP2023507739A publication Critical patent/JP2023507739A/ja
Publication of JP2023507739A5 publication Critical patent/JP2023507739A5/ja
Priority to JP2024218275A priority Critical patent/JP7821870B2/ja
Application granted granted Critical
Publication of JP7624995B2 publication Critical patent/JP7624995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537007A 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法 Active JP7624995B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218275A JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218275A Division JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023507739A JP2023507739A (ja) 2023-02-27
JP2023507739A5 true JP2023507739A5 (https=) 2023-12-26
JP7624995B2 JP7624995B2 (ja) 2025-01-31

Family

ID=76478538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
JP2024218275A Active JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218275A Active JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Country Status (21)

Country Link
US (11) US20210353593A1 (https=)
EP (2) EP4076652B1 (https=)
JP (2) JP7624995B2 (https=)
KR (1) KR20230015874A (https=)
CN (3) CN116173014A (https=)
AU (1) AU2020404984A1 (https=)
BR (1) BR112022012075A2 (https=)
CA (1) CA3161516A1 (https=)
DK (1) DK4076652T3 (https=)
FI (1) FI4076652T3 (https=)
HR (1) HRP20260121T1 (https=)
IL (1) IL293921A (https=)
LT (1) LT4076652T (https=)
MX (1) MX2022007471A (https=)
PH (1) PH12022551456A1 (https=)
PL (1) PL4076652T3 (https=)
PT (1) PT4076652T (https=)
RS (1) RS67746B1 (https=)
SI (1) SI4076652T1 (https=)
TW (1) TWI875895B (https=)
WO (1) WO2021126977A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
CN119325377A (zh) * 2022-05-19 2025-01-17 奇努克治疗公司 用阿曲生坦治疗局灶节段性肾小球硬化的方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2024076177A1 (ko) * 2022-10-05 2024-04-11 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
AU2023366516A1 (en) * 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
JP2025536433A (ja) 2022-11-07 2025-11-05 サンレノ セラピューティクス （シャンハイ） リミテッド ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
KR100964908B1 (ko) 2002-03-22 2010-06-23 깃세이 야쿠힌 고교 가부시키가이샤 신장질환의 예방 또는 치료제
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
EP1802610A1 (en) 2004-09-17 2007-07-04 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
EP2012751A4 (en) 2006-03-21 2010-11-24 Morehouse School Of Medicine NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION
BRPI0709411A2 (pt) * 2006-03-27 2011-07-12 Genentech Inc método para tratamento de uma doença renal
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2667364A1 (en) 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
EP2509594A1 (en) 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
CN103025670B (zh) 2010-07-28 2016-08-10 日本电气硝子株式会社 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
US9364458B2 (en) * 2013-07-08 2016-06-14 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
AU2015342929A1 (en) * 2014-11-07 2017-05-25 Abbvie Inc. Methods of treating CKD using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
KR102528260B1 (ko) 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
CN117017985A (zh) * 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
CA3161516A1 (en) * 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
IL297208A (en) 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Similar Documents

Publication Publication Date Title
JP2023507739A5 (https=)
Breedveld et al. Leflunomide: mode of action in the treatment of rheumatoid arthritis
Dueñas-González et al. The prince and the pauper. A tale of anticancer targeted agents
Kirtschig et al. Interventions for bullous pemphigoid
Wei et al. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling
JP7624995B2 (ja) アトラセンタンによるｉｇａ腎症を治療する方法
WO2020041243A1 (en) Methods related to bronchial premalignant lesion severity and progression
Deininger Resistance to imatinib: mechanisms and management
AU2003233576A8 (en) Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2012061683A2 (en) Methods for treating cancer
Santoni et al. Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
WO2014093750A1 (en) Method of administration and treatment
EP3528806B1 (en) Pharmaceutical compounds
US8598188B2 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US20150216865A1 (en) Methods of treating a bruton's tyrosine kinase disease or disorder
CN119923258A (zh) 在wnt通路肿瘤阻抑基因中具有突变的癌症的治疗
WO2021250546A1 (en) Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
KR20220070243A (ko) 순차적 치료 환경에서 면역 체크포인트 억제제에 대한 환자 반응을 향상시키기 위한 fgfr-유전적으로 변경된 암에서의 fgfr 억제제의 용도
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
RU2855917C1 (ru) Сатраплатин для применения при лечении лимфоидных неоплазм
TWI914232B (zh) 用阿曲生坦(ATRASENTAN)治療IgA腎病的方法
Liao et al. Comparative Safety and Immunological Effects of Tocilizumab versus Cyclophosphamide in Takayasu Arteritis: A Retrospective Cohort Study
US8992947B2 (en) Method for predicting therapeutic effect of chemotherapy on renal cell cancer
WO2025062016A2 (en) Biomarkers for tlr inhibitor treatment
AU2024347751A1 (en) Biomarkers for tlr inhibitor treatment